Legend Biotech reports Q4 EPS (40c), consensus (83c)

Reports Q4 revenue $79.46M, consensus $86.35M. “With worldwide sales of half a billion dollars in its first full year of commercialization, our rapid, successful launch of CARVYKTI(R) reinforces its position as a leading CAR-T therapy for patients with relapsed and refractory multiple myeloma,” said Ying Huang, CEO of Legend Biotech. “Our accomplishments in 2023, through our strategic partnership with Johnson & Johnson*, created the foundation for strong growth and uptake of CARVYKTI(R), positioning us to bring CARVYKTI(R) to more patients in need of treatment going forward.”